Monitor future Form 4 filings for any insider transactions by William Ho, which could signal his view on the company's prospects. The appointment of a new director is routine and does not warrant immediate action.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $1.02entry
- T+1 · 5d ago −1.96%α −1.61% · $1.00
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
William Ho, M.D., Ph.D., filed a Form 3 initial statement of beneficial ownership with Spero Therapeutics, Inc., indicating he has become a director (and possibly officer or 10% shareholder) of the company. The filing is accompanied by a standard power of attorney authorizing company officers to execute future Section 16 filings on his behalf. This is a routine administrative filing with no material financial impact.
Key Facts
- William Ho filed a Form 3 initial statement of beneficial ownership with Spero Therapeutics, Inc.
- The filing was made on November 10, 2026, with a period of report of November 10, 2026.
- A power of attorney (Exhibit 24.1) was executed on November 9, 2026, authorizing Esther Rajavelu, Sheila Finan, and Maegan Deare to execute Forms 3, 4, and 5 on behalf of William Ho.
- William Ho is identified as a director of Spero Therapeutics, Inc.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-455868 |
| Document: 0001193125-26-455868-index-headers.html | 0001193125-26-455868 |
| Document: 0001193125-26-455868-index.html | 0001193125-26-455868 |
| Document: 0001193125-26-455868.txt | 0001193125-26-455868 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Viewing Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers